CN103829254A - Application of proanthocyanidins in preparing diet food or drug - Google Patents

Application of proanthocyanidins in preparing diet food or drug Download PDF

Info

Publication number
CN103829254A
CN103829254A CN201310714293.5A CN201310714293A CN103829254A CN 103829254 A CN103829254 A CN 103829254A CN 201310714293 A CN201310714293 A CN 201310714293A CN 103829254 A CN103829254 A CN 103829254A
Authority
CN
China
Prior art keywords
opc
proanthocyanidins
application
food
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310714293.5A
Other languages
Chinese (zh)
Inventor
陈卫
苏鸿铭
郑晓冬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN201310714293.5A priority Critical patent/CN103829254A/en
Publication of CN103829254A publication Critical patent/CN103829254A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses an application of proanthocyanidins in preparing diet food or drug, and discloses an application of a drug composition with proanthocyanidins as an active component and pharmaceutically acceptable additives in preparing the diet food or drug. Mice experiments demonstrate that proanthocyanidins has obvious reduction effects for growth rate of mice body weight, food utilization rate and body fat and presents a dose-dependent relationship, can effectively reduce blood glucose level and serum cholesterol level of the mice, and can increase serum free fatty acid level and oxidation resistant level. Novel medical application and novel application field are developed for proanthocyanidins. Experiments show that the concentration of proanthocyanidins required for treating obesity is relatively low; proanthocyanidins has no side or toxic effect and has the functions of protecting human body blood circulation, enhancing immunity and protecting eyesight, thereby guaranteeing effectiveness of weight reduction and playing a promotion effect for body health.

Description

A kind of OPC is in the application of preparing in diet food or medicine
Technical field
The present invention relates to Chinese medicine applied technical field, be specifically related to a kind of OPC in the application of preparing in diet food or medicine.
Background technology
Obesity (obesity) refers to body control volume fat, the disorder of energy metabolism balance mechanism, thereby causes body fat overheap or abnormal distribution to cause body quality to increase, and is a kind of multifactorial chronic metabolic disease.In recent years, no matter be developed country or the puzzlement that is all faced with obesity accelerated development in the developing country of economic reform and Model of Nutrition transition, bring huge medical expense and burden on society thereupon.Oneself classifies obesity one of as the world today's four large medical science social concerns the World Health Organization (WHO), and is confirmed as the highest chronic disease of global adult's illness rate.
Adipose tissue is the metabolic organ that body weight for humans is wanted, and it can be secreted a large amount of cell factors and participate in multinomial physiology course.On microcosmic, the fat form of expression is that adipocyte number increases and cell volume increase.
Natural bioactivity substance has certain effect of weight reducing as genistein, conjugate linolenic acid, myricetin, DHA, catechin, Quercetin, resveratrol, 4,5,9-trithiadodeca-1,6,11-triene 9-oxide etc. have been proved to be in vivo with external, its main manifestations is at different differential period affecting lipocytes, can induce front adipocyte generation apoptosis, suppress Adipocyte Differentiation, become fat, or promote lipid to decompose.
OPC (Procyanidins, molecular formula C 30h 26o 12) be the poly-polyphenol compound that occurring in nature extensively exists, this compounds has multiple biologically active, and it is with efficient, low toxicity, high bioavilability and famous.Research shows that OPC has the blood circulation of improvement, vision protection, elimination oedema, the effects such as cholesterol that reduce.
The patent documentation that is CN102600127A as publication number discloses OPC or the application in medicine or the health food of preparation prevention or treatment disorders of lipid metabolism disease containing its plant extracts.Publication number is that the OPC that the patent documentation of CN102940624A discloses in Chinese traditional medicine cinnamon water extract is treated the application in diabetes medicament in preparation, research discovery Chinese cassia tree OPC can be assembled as target spot take anti-IAPP, in preparation treatment diabetes B medicine, has great using value.Publication number is that the patent documentation of CN1745747B discloses the purposes of a kind of OPC at preparation treatment colitis medicine, especially discloses the purposes of OPC at preparation treatment ulcerative colitis medicine.
At present, that carries out for the research of OPC purposes is comparatively deep, but the effect of weight reducing of OPC is not yet had to patent literature.Natural for developing, safe and effective weight losing function food and medicine are provided certain scientific basis by the present invention.
Summary of the invention
The invention provides a kind of OPC in the new application of preparing in diet food or medicine, expanded the application of OPC.
The invention discloses a kind of OPC in the application of preparing in diet food or medicine.
The invention also discloses a kind of using OPC as active component and the pharmaceutical composition that can accept additives in pharmaceutics in the application of preparing in diet food or medicine.
As preferably, described OPC separation and Extraction from natural berry obtains.The extraction of described OPC can be according to prior art separation and Extraction from natural berry.
As preferably, described natural berry is blueberry, raspberry, blackberry, blueberry, mulberries or strawberry.
Concrete extracting method can the patent documentation that be CN101712673B referring to publication number in disclosed method.
OPC described in the present invention also can be by directly buying and obtain.
Described OPC molecular formula is:
The diet food of described preparation can be beverage based food.
Described slimming medicine can be any applicable regular dosage form, and wherein, the consumption of contained OPC, more than effective dose, can be selected as the case may be, is generally 50～300mg/kg/ days, is preferably 200～300mg/kg/ days.
Prove by mouse experiment: OPC has obvious reducing effect to weight of mice rate, food utilization, body fat, and be dose-dependence; Mouse blood sugar level, serum cholesterol level be can effectively reduce, serum free fatty acid levels, antioxidant levels improved.
Compared with prior art, tool of the present invention has the following advantages:
1, the present invention is that OPC has been excavated new medical application, has opened up a new application;
2, to found through experiments OPC lower to the required concentration for the treatment of of obesity in the present invention, has no side effect;
3, OPC has protection blood circulation of human body, strengthens the effects such as immunity, vision protection, has not only guaranteed the validity of fat-reducing, and body health is also played to facilitation.
Accompanying drawing explanation
Fig. 1 is each test group Mouse Weight increment relation curve in time in embodiment 1; (* p<0.05, * * p<0.01 is compared with HFD)
Fig. 2 is the impact of OPC on C57BL/6 mouse food ration (Food) and food utilization (Food); (* p<0.05, * * p<0.01 is compared with HFD)
Fig. 3 is the impact of OPC on C57BL/6 mouse liver (A) and adipose tissue (B) weight; (* p<0.05, * * p<0.01 is compared with HFD)
Fig. 4 is that OPC is on C57BL/6 mouse blood sugar (A), serum TAC (B), MDA(C) impact.(* p<0.05, * * p<0.01 is compared with HFD);
Fig. 5 is that OPC is on C57BL/6 mouse liver TC(A), TG(B), the impact of SOD enzyme activity (C), free fatty (D) level.(* p<0.05, * * p<0.01 is compared with HFD);
Fig. 6 is the impact of OPC on C57BL/6 mouse adipose tissue, liver organization form.(* p<0.05, * * p<0.01 is compared with HFD).
the specific embodiment
Below in conjunction with specific embodiment, the invention will be further described, and what below enumerate is only specific embodiments of the invention, but protection scope of the present invention is not limited in this:
Embodiment 1
OPC beverage (according to mass fraction):
OPC 0.2%, citric acid 0.1%, honey 4.35%, Aspartame 1.5%, vanilla 0.05%, water 93.8%.
According to the mass fraction of above-mentioned formula, by 20 grams of OPCs, 1 gram of citric acid, 435 grams of honey, 150 grams of Aspartames, 5 grams of vanillas of vanilla, 9380g water mixes, and boils sterile filling beverage bottle and get final product.Every bottle of 200ml, 400 milligrams/bottle of procyanidin content.
Dosage for being grown up: take each 1 bottle every day 1 time.
Embodiment 2
OPC capsule (according to mass fraction):
OPC 30%, gelatin 18%, CPP 27.5%, dolomol 1.5%, D-mannital 23%.
According to the mass fraction of above-mentioned formula, by OPC 30g, 18 grams, gelatin, is dissolved in 150 grams of water, the dry OPC microcapsule granule of making of spraying.27.5 grams of CPPs, 23 grams of D-mannitals, 1.5 grams of dolomols and microcapsule granule are put into multidigit mixer and are fully mixed, and make wet grain, cross 20 mesh sieves, dry, and whole grain is made capsule with capsule filler packing.250mg/ grain, procyanidin content 75mg/ grain.
Dosage for being grown up: take each 2 every day 2 times.
Fat-reducing effect test
Test one: observe the impact of OPC on obesity mice body weight, investigate the weight that whether can reduce obesity mice liver and adipose tissue.
Experiment material:
Clean level C57BL/6 mouse, purchased from Shanghai Slac Experimental Animal Co., Ltd.;
OPC (purity >95%) is purchased from National Institute for Food and Drugs Control;
Experimental technique:
Modeling and intervention: before experiment, 65 C57BL/6 mouse are given under experimental enviroment to the conventional raising of basal feed 5 days, after conforming, be divided at random 12 of low fat control groups, 53 of hyperlipidemia model groups.Low fat control group gives 10% low fat feed (LFD), and all the other hyperlipidemia model groups all give 45% high lipid food (HFD).After 2 weeks, eliminate in hyperlipidemia model group insensitive 5 mouse of hyperlipidemia model according to body weight, 48 remaining mouse are divided into 4 groups, 12 every group at random.Mice group, administration and feed arrange the test grouping in Table 1-C57BL/6 mouse prevention of obesity model.
Table 1
Figure BDA0000442744350000051
Feeding environment and operation: 4, the every cage of mouse; Environment temperature (22 ± 2) ℃; Humidity 40-70%; Natural lighting; Mouse ad lib and drinking-water; Record body weight and food ration every day, the intervention experiment of OPC continues 10 weeks.
After experiment finishes, respectively organize mouse fasting 12h.Weigh, pluck eyeball blood sampling, put to death, get liver, adipose tissue, and weigh.Body weight gain rate, food utilization computing formula are as follows:
Figure BDA0000442744350000052
Figure BDA0000442744350000053
Experimental result:
The impact of OPC on Mouse Weight, food ration:
Fig. 1 shows that the increased weight of 3 concentration administration groups of OPC is all starkly lower than hyperlipidemia model group, and presents certain dosage effect.300mg/kg/d(OPC.H group) OPC the most remarkable to the inhibition of high fat diet inducing obesity, hyperlipidemia model group body weight increment rate is 39.7 ± 5.9%, and OPC.H group body weight increment rate is only 9.4 ± 3.7%.
Fig. 2 shows that food ration (food intake), the energy intake of OPC to each experimental group C57BL/6 mouse has certain influence, and the food ration of 3 dosage groups all decreases compared with hyperlipidemia model group.OPC is remarkable to the impact effect of food utilization (food utilization rate), the food utilization of low dose group be high fat group 60.4%, middle dosage group is 38.7%, high dose group is only 29.4%, showing the main intervention effect of OPC to Mouse Weight, is not by suppressing food ration.
The impact of OPC on mouse liver, adipose tissue weight:
Fig. 3 (A) shows, high lipid diet has remarkable impact to mouse liver, and hyperlipidemia model group is compared with low fat model group mouse, and liver weight significantly increases, low dosage OPC has certain influence to liver weight, and middle and high dosage can effectively reduce the hepatomegaly of meals.Fig. 3 (B) shows that OPC.H group is compared with HFD group, and fatty gross weight declines 52.6%, and effect is remarkable.
Test two: observe the impact of OPC on obesity mice blood sugar, MDA (MDA), investigate the serum TAC (T-AOC) that whether can improve obesity mice.
Experiment material:
Clean level C57BL/6 mouse, purchased from Shanghai Slac Experimental Animal Co., Ltd.;
OPC (purity >95%), purchased from National Institute for Food and Drugs Control;
MDA (MDA) measure kit, TAC (T-AOC) measure kit,, determination of protein concentration kit, build up bio tech ltd purchased from Nanjing.
Experimental technique:
The modeling of C57BL/6 mouse and interference method are with embodiment 1.
The mensuration of C57BL/6 mice serum index: the centrifugal 15min of 3000r/min after mouse blood room temperature leaves standstill, separation of serum, packing ,-20 ℃ are frozen.Utilize automatic clinical chemistry analyzer to measure blood sugar.Measure serum MDA, T-AOC according to detection kit.
Experimental result: as shown in Fig. 4 (A), high lipid diet can significantly improve 42.9% mouse blood sugar level, give OPC after mouse blood sugar level obviously reduce, and be dose-dependence, high dose OPC can reduce by 38.5% mouse blood sugar level, and effect is remarkable.As shown in Fig. 4 (B), high lipid diet can effectively reduce by 13.9% mice serum T-AOC level, OPC.M group, OPC.H group compared with HFD component you can well imagine high by 15.1%, 22.5%.Fig. 4 (C) demonstration, high lipid diet significantly improves 51.7% mouse MDA level, and middle dosage OPC OPC.M group is compared compared with HFD group, and MDA reduces by 27.4%, and high dose group OPC.H action effect is suitable with middle dosage.
Above result shows, the blood sugar level that OPC can effectively reduce high lipid diet induction rises, and by improving TAC in body, reduces body lipid levels of peroxide.
Test three: observe the impact of OPC on obesity mice liver cholesterol (TC), triglyceride (TG), investigate and whether can promote adipose tissue to decompose, improve the liver oxidation resistance of obesity mice.
Experiment material:
Clean level C57BL/6 mouse, purchased from Shanghai Slac Experimental Animal Co., Ltd.;
OPC (purity >95%) is purchased from National Institute for Food and Drugs Control;
Superoxide dismutase (SOD) is measured kit, free fatty (FFA) is measured kit, determination of protein concentration kit, builds up bio tech ltd purchased from Nanjing.
Experimental technique:
The modeling of C57BL/6 mouse and interference method are with embodiment 1.
Liver fat index determining: get appropriate liver cooling in ice, the cold extraction buffer that adds 4 times of weight (contains 0.07mol/L KHCO in the phosphate buffer of 0.1mol/L pH7.8 3, 1mmol/LEDTA, 1mmol/L DTT), high-speed homogenization 1min, then 4 ℃ of centrifugal 30min of 10000r/min immediately, obtain supernatant.Utilize Biochemical Analyzer to measure TG, TC.Measure liver F FA, SOD, protein concentration according to detection kit.
Experimental result: Fig. 5 (A) demonstration, high lipid diet significantly improves 50.5% mouse liver TC level, and OPC.H group significantly reduces by 17.5% compared with HFD group.As Fig. 5 (B) shows, high lipid diet can effectively improve 47.7% mouse liver TG level, and OPC.M group, OPC.H group reduce respectively 18.4%, 27.3% compared with the TG level of HFD group.Fig. 5 (C) demonstration, high lipid diet reduces superoxide dismutase (SOD) vigor of 15.4% mouse liver, and OPC.H group significantly raises 27.8% compared with HFD group.Fig. 5 (D) demonstration, OPC.M group liver free fatty (FFA) level is compared with nearly one times of the remarkable rising of HFD component, and effect of high dosage effect is suitable with middle dosage.Above result shows, OPC can effectively promote adipose tissue to decompose, and maintains Liver Lipid Metabolism balance, improves liver oxidation resistance.
Test four: investigate OPC and whether can suppress the accumulation of adipose tissues decomposition cytolipin, promote adipocyte smaller volume.
Experiment material:
Clean level C57BL/6 mouse, purchased from Shanghai Slac Experimental Animal Co., Ltd.;
OPC (purity >95%) is purchased from National Institute for Food and Drugs Control;
Oil red O is purchased from Aladdin reagent company.
Experimental technique:
The modeling of C57BL/6 mouse and interference method are with embodiment 1.
C57BL/6 mouse epididymis is the observation by light microscope of adipose tissue around: 1. get epididymis adipose tissue one fritter around, 10% formalin is fixed, and makes tissue fixing completely, abundant; 2. the hepatic tissue blocking fixing is dewatered, transparent; 3. waxdip, embedding section; 4. haematoxylin dyeing; 5. neutral gum mounting drying; 6. under 200 power microscopes, observe the adipocyte state of adipose tissue.
Experimental result: as shown in Figure 6, LFD group, adipocyte small volume, form is clear, structural integrity; The epididymis of HFD group around adipocyte volume expands, and cell size is inhomogeneous, irregular arrangement; The each dosage group of OPC is compared with HFD group, and adipocyte volume obviously reduces, in 200 power microscope field range fat cell hypertrophy number showed increased; OPC.H group adipocyte volume is even less than low fat control group, the compact rule of cell arrangement, and form is clear.These results show that OPC is remarkable to the inhibition of C57BL/6 mouse fat tissue cell lipid accumulation.
Finally, the present invention can summarize with other the concrete form without prejudice to spirit of the present invention and principal character.Therefore, no matter from that, above-mentioned embodiment of the present invention all can only think explanation of the present invention can not limit the present invention, claims have been pointed out scope of the present invention, and scope of the present invention is not pointed out in above-mentioned explanation, therefore, any change in implication and the scope suitable with claims of the present invention, all should think to be included in the scope of claims.

Claims (4)

1. an OPC is in the application of preparing in diet food or medicine.
One kind using OPC as active component and the pharmaceutical composition that can accept additives in pharmaceutics in the application of preparing in diet food or medicine.
3. application as claimed in claim 1 or 2, is characterized in that, described OPC separation and Extraction from natural berry obtains.
4. application as claimed in claim 3, is characterized in that, described natural berry is blueberry, raspberry, blackberry, blueberry, mulberries or strawberry.
CN201310714293.5A 2013-12-20 2013-12-20 Application of proanthocyanidins in preparing diet food or drug Pending CN103829254A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310714293.5A CN103829254A (en) 2013-12-20 2013-12-20 Application of proanthocyanidins in preparing diet food or drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310714293.5A CN103829254A (en) 2013-12-20 2013-12-20 Application of proanthocyanidins in preparing diet food or drug

Publications (1)

Publication Number Publication Date
CN103829254A true CN103829254A (en) 2014-06-04

Family

ID=50793404

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310714293.5A Pending CN103829254A (en) 2013-12-20 2013-12-20 Application of proanthocyanidins in preparing diet food or drug

Country Status (1)

Country Link
CN (1) CN103829254A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106136247A (en) * 2016-07-01 2016-11-23 北京斯利安药业有限公司 A kind of Semen Phaseoli Vulgaris many certain kind of berries compositions and preparation method thereof
CN107581613A (en) * 2017-10-26 2018-01-16 广州静道科技应用有限公司 A kind of high protein weight reducing meal replacement powder and preparation method thereof
CN108434314A (en) * 2018-04-24 2018-08-24 刘晓华 A kind of formula and application method of slimming

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024245A1 (en) * 2001-09-20 2003-03-27 N.V. Nutricia Composition for reducing appetite in mammals comprising proxyanidin
CN1824094A (en) * 2005-12-23 2006-08-30 上海交大昂立股份有限公司 Health protection food possessing body fat reducing function
CN101642445A (en) * 2008-08-08 2010-02-10 中国科学院兰州化学物理研究所 Procyanidin capsules and process for manufacturing same
CN102028283A (en) * 2010-12-09 2011-04-27 孙国臣 Health care drink for clearing away free radicals of human body and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024245A1 (en) * 2001-09-20 2003-03-27 N.V. Nutricia Composition for reducing appetite in mammals comprising proxyanidin
CN1824094A (en) * 2005-12-23 2006-08-30 上海交大昂立股份有限公司 Health protection food possessing body fat reducing function
CN101642445A (en) * 2008-08-08 2010-02-10 中国科学院兰州化学物理研究所 Procyanidin capsules and process for manufacturing same
CN102028283A (en) * 2010-12-09 2011-04-27 孙国臣 Health care drink for clearing away free radicals of human body and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
戚向阳，等: "苹果原花青素的稳定性及其保健饮品的研究", 《食品科技》 *
无: "Separation and purification of proanthocyanidin, involves separating proanthocyanidin from raw material based on polymerization degree, and purifying proanthocyanidin by reversed phase liquid chromatography using modified silica gel", 《德文特数据库》 *
闫少芳，等: "葡萄籽提取物原花青素对肥胖高脂血症大鼠的作用研究", 《中国预防医学杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106136247A (en) * 2016-07-01 2016-11-23 北京斯利安药业有限公司 A kind of Semen Phaseoli Vulgaris many certain kind of berries compositions and preparation method thereof
CN107581613A (en) * 2017-10-26 2018-01-16 广州静道科技应用有限公司 A kind of high protein weight reducing meal replacement powder and preparation method thereof
CN108434314A (en) * 2018-04-24 2018-08-24 刘晓华 A kind of formula and application method of slimming

Similar Documents

Publication Publication Date Title
Li et al. A-type procyanidins from litchi pericarp ameliorate hyperglycaemia by regulating hepatic and muscle glucose metabolism in streptozotocin (STZ)-induced diabetic mice fed with high fat diet
Yuan et al. Hypoglycemic and anti-inflammatory effects of seabuckthorn seed protein in diabetic ICR mice
Lei et al. The antioxidant effect of Asparagus cochinchinensis (Lour.) Merr. shoot in D-galactose induced mice aging model and in vitro
Land Lail et al. Berries as a treatment for obesity-induced inflammation: Evidence from preclinical models
Ulbricht et al. An evidence-based systematic review of acai (Euterpe oleracea) by the Natural Standard Research Collaboration
CN104983791A (en) Health-care product containing coenzyme Q10 and preparation method thereof
CN104288345A (en) A traditional Chinese medicine composition assisting blood lipid reduction and a preparing method thereof
CN102631405A (en) Compound apigenin nanoemulsion antihypertensive drug
Zarei et al. Hypoglycemic and hypolipidemic activities of Salvia hydrangea in streptozotocin-induced diabetes in rats
Żary-Sikorska et al. Protective effects of a strawberry ellagitannin-rich extract against pro-oxidative and pro-inflammatory dysfunctions induced by a high-fat diet in a rat model
CN103734696B (en) A kind of soft capsule and preparation method thereof improving immunity, protection internal organs
Hasan et al. Hypoglycemic activity of methanolic leaf extract of Blumea lacera in Swiss-albino mice
Bahari Effect of Elateriospermum tapos extract as coadjuvant in ameliorating maternal obesity on female offspring at weaning
Aja et al. Evaluation of anti-diabetic effect and liver enzymes activity of ethanol extract of Pterocarpus santalinoides in alloxan induced diabetic albino rats
CN103829254A (en) Application of proanthocyanidins in preparing diet food or drug
CN103766901A (en) Application of andrographolide C to preparation of weight-losing food or medicine
CN104415135B (en) The purposes of hydroxyl polymethoxyflavone class compound and/or its derivative
AU2012325600B2 (en) Pharmaceutical composition regulating blood fat and preparation process thereof
CN101904856A (en) Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products
CN1262284C (en) Health care product of hippophae rhamnoides oil
CN106727480A (en) Applications of the Fex-3 in anti-obesity medicine is prepared
Anadon et al. Acute and repeated dose (28 days) oral safety studies of an alkoxyglycerol extract from shark liver oil in rats
Chu et al. The protective effects of mangiferin on metabolic and organs functions in the adolescent rat model of alcohol abuse
Deckmann et al. Common pregnancy complications and polyphenols intake: an overview
Bo Research on the influence of anti-fatigue effect and movement ability of blueberry polysaccharides on aged mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140604